

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



BrainAurora Medical Technology Limited

脑动极光医疗科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 6681)

VOLUNTARY ANNOUNCEMENT COGNITIVE FUNCTION ASSESSMENT PRODUCT FOR PATIENTS WITH DEPRESSION GRANTED CLASS II MEDICAL DEVICE REGISTRATION CERTIFICATE BY THE BEIJING MUNICIPAL MEDICAL PRODUCTS ADMINISTRATION

This announcement is made by BrainAurora Medical Technology Limited 脑动极光医疗科技有限公司 (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis for the purposes of keeping the investors informed of the latest update on the business developments of the Group.

The board of directors (the “**Board**”) of the Company is pleased to announce that in the late afternoon of October 27, 2026, the Company received the Class II Medical Device Registration Certificate for its cognitive function assessment software for patients with depression, issued by the Beijing Municipal Medical Products Administration (the “**Beijing Administration**”), and the relevant information is disclosed as follows:

I. REGISTRATION CERTIFICATE AND PRODUCT PROFILE

The product is cognitive function assessment software with the model number BJHZ-NACT. It is registered as a Class II medical device under Registration Certificate No. Jing Xie Zhu Zhun 20262210410, issued by the Beijing Administration, which the Company received in the late afternoon of October 27, 2026. The product is standalone software for cognitive function assessment in patients with depression. It assesses and reports results across four dimensions – memory, attention, executive function and information processing speed – enabling clinicians to understand patients’ cognitive status and providing safe and effective medical support for subsequent treatment. The clinical trial of the product was initiated in September 2024 and completed in August 2025.

II. BACKGROUND AND SIGNIFICANCE TO THE GROUP

Cognitive symptoms persist throughout the course of depression, adversely affecting the response and remission rates of antidepressant treatment, increasing the risk of relapse, and preventing some patients from regaining normal social functioning, thereby imposing a significant social and economic burden.

The product is the first medical device registration certificate obtained by the Company from the Beijing Administration, and the first medical device registration certificate for cognitive function assessment in the depression field. It marks a registration breakthrough by the Company in cognitive assessment for mental disorders, gives the Company a first-mover advantage in the market, and further enhances the Company's digital therapeutics product portfolio for cognitive disorders. The Board believes that this registration achievement will further consolidate the Group's industry-leading position in the fields of digital therapeutics for cognitive disorders and is in the overall interests of the Group and its shareholders.

THE COMPANY MAY NOT BE ABLE TO ULTIMATELY COMMERCIALIZE AND MARKET THE RELEVANT QUANTITATIVE COGNITIVE ASSESSMENT SOFTWARE FOR DEPRESSION PRODUCT SUCCESSFULLY. SHAREHOLDERS OF THE COMPANY AND POTENTIAL INVESTORS ARE ADVISED TO EXERCISE DUE CARE WHEN DEALING IN THE SHARES OF THE COMPANY.

The contents of this announcement do not constitute a connected transaction or a notifiable transaction under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

By order of the Board
BrainAurora Medical Technology Limited
脑动极光医疗科技有限公司
Tan Zheng
Chairman and Executive Director

Hong Kong, October 27, 2026

As at the date of this announcement, the Board comprises: (i) Mr. Tan Zheng as executive director; (ii) Mr. Deng Feng, Mr. Yang Fan and Ms. Wang Jingbo as non-executive directors; and (iii) Mr. Lam Yiu Por, Dr. Duan Tao and Mr. Tu Lei as independent non-executive directors.